human recombinant dHGF (CSB-001) / Claris Biotherap - LARVOL DELTA

CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - P1 | N=65 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | Trial completion date: Aug 2025 ➔ May 2026 | Trial primary completion date: Aug 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Ophthalmology

CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - P1 | N=65 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | N=40 ➔ 65

Enrollment change • Ophthalmology

CSB-C23-002: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Corneal Abrasion • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | N=20 ➔ 40

Enrollment change • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2 | N=131 | Completed | Sponsor: Claris Biotherapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Keratitis • Ocular Inflammation • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2 | N=128 | Active, not recruiting | Sponsor: Claris Biotherapeutics, Inc. | Trial primary completion date: Apr 2024 ➔ Jul 2024 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Claris Biotherapeutics, Inc.

New P1 trial • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Claris Biotherapeutics, Inc.

New P1 trial • Corneal Abrasion • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2 | N=128 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Nov 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2 | N=108 | Recruiting | Sponsor: Claris Biotherapeutics, Inc. | Trial completion date: Feb 2023 ➔ Feb 2024 | Trial primary completion date: Nov 2022 ➔ Nov 2023

Trial completion date • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2; N=108; Recruiting; Sponsor: Claris Biotherapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Keratitis • Ocular Inflammation • Ophthalmology

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - P1/2; N=108; Not yet recruiting; Sponsor: Claris Biotherapeutics, Inc.

Clinical • New P1/2 trial • Keratitis • Ocular Inflammation • Ophthalmology